Abstract Library

#3072 Rb and p53 Status Determination by Immunochemistry Is Complementary in Routine Practice to Genetic Testing of Neuroendocrine Neoplasms

Introduction: Rb and p53 status may help distinguishing well from poorly differentiated neuroendocrine neoplasms (NEN) and may predict response to chemotherapy. Studies correlating Rb/p53 genetic and immunohistochemistry were performed on high-quality frozen samples with high throughput techniques efficient for copy number determination. This situation differs from routine practice in which small deletions may be hard to detect on formalin-fixed paraffin-embedded (FFPE) samples with a gene panel approach.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Cros J

Authors: Chen R, Lacroix L, De Rycke O, Lacombe C, Cazes A,

Keywords: rb, p53, aggressive neuroendocrine tumors, biomarker,

#3062 The Splicing Factor CELF4 Is Dysregulated in Neuroendocrine Tumors, Where It Can Enhance Aggressiveness Features

Introduction: There is increasing evidence that alterations in alternative splicing are linked to key tumor features in different cancers. Besides mutations, dysregulation of the splicing machinery would represent the main underlying cause for these alterations. Indeed, splicing dysregulation is emerging as a novel, transversal cancer hallmark, due to its association with multiple dysfunctions in tumor cells.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Alors-Pérez E

Authors: Alors-Pérez E, Pedraza-Arévalo S, Vázquez-Borrego M, Blázquez-Encinas R, Herrera-Martínez A,

Keywords: PanNET, CELF4, splicing, aggressiveness, pituitary tumors,

#3055 Dynamics of Changes in Chromogranin A Concentration as a Prognostic Factor Radiopeptide Therapy in Neuroendocrine Tumours

Introduction: Chromogranin A (CgA) is a non-specific marker of neuroendocrine tumors (NET) and its significantly increased level is an unfavorable prognostic factor while the decrease in CgA during biotherapy with somatostatin analogs (SSA) correlates with the increase in profession free survival (PFS).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Sygula A, Jurecka-Lubieniecka B, Hasse-Lazar K, Michalik B, Ledwon A,

Keywords: CgA, PRRT, prognosis,

#3050 Radioembolization for Neuroendocrine Liver Metastases: An Institutional Case Series, Systematic Review and Meta-Analysis

Introduction: Neuroendocrine liver metastases are clinically challenging and often non-resectable due to their frequent disseminated distribution. Radioembolisation with yttrium-90 labelled microspheres represents an emerging modality for NELM.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Clift A

Authors: Clift A, Frilling A, Braat A, Alsafi A, Wasan H,

Keywords: liver, metastases, radioembolization, yttrium, selective internal radiation therapy,

#3045 Reliability and Agreement of Radiological and Pathological Tumor Size in Patients with MEN1-Related Pancreatic Neuroendocrine Tumors: Results from a Population-Based Cohort

Introduction: Pancreatic neuroendocrine tumors (pNETs) are the most lethal manifestation in patients with multiple endocrine neoplasia type 1 (MEN1). Tumor size is still regarded as the main prognostic factor and therefore used for surgical decision making.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: van Beek D

Authors: van Beek D, Verkooijen H, Bonsing B, van Eijck C, van Goor H,

Keywords: Multiple endocrine neoplasia type 1, pancreatic neuroendocrine tumor, reliability, agreement, computed tomography, magnetic resonance imaging, endoscopic ultrasonography, pathology,